EI
KRON

Ellevest Inc’s Kronos Bio KRON Stock Holding History

Ellevest Inc’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-599
Closed -$875 – 1033
2023
Q1 		$875 Hold
599
– – ﹤0.01% 1597
2022
Q4 		$970 Buy
599
+407
+212% +$937 ﹤0.01% 1528
2022
Q3 		$1K Buy
192
+184
+2,300% +$831 ﹤0.01% 1475
2022
Q2 		$0 Sell
8
-6
-43% -$27 ﹤0.01% 1537
2022
Q1 		$0 Buy
+14
New +$119 ﹤0.01% 1525

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ellevest Inc's KRON Position: Q2 2023 in Review

Ellevest Inc sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 599 shares — an estimated $875 sold.

Ellevest Inc first reported a position in KRON in Q1 2022 and held it in 5 quarters. The position peaked at $1K in Q3 2022. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Ellevest Inc reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 599 Kronos Bio shares in Q2 2023, an estimated $875.
  • Ellevest Inc first reported a position in Kronos Bio in Q1 2022 and held it in 5 quarters.
  • Ellevest Inc's Kronos Bio position peaked at $1K in Q3 2022.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.